American Journal of Ophthalmology
Volume 147, Issue 2 , Pages 198-205.e1 , February 2009

Tear Cytokine Profiles in Dysfunctional Tear Syndrome

  • Helene Lam

      Affiliations

    • Department of Ophthalmology, Ocular Surface Center, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
    • ,
  • Lauren Bleiden

      Affiliations

    • Department of Ophthalmology, Ocular Surface Center, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
    • ,
  • Cintia S. de Paiva

      Affiliations

    • Department of Ophthalmology, Ocular Surface Center, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
    • ,
  • William Farley

      Affiliations

    • Department of Ophthalmology, Ocular Surface Center, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
    • ,
  • Michael E. Stern

      Affiliations

    • Department of Ophthalmology, Ocular Surface Center, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
    • ,
  • Stephen C. Pflugfelder

      Affiliations

    • Department of Ophthalmology, Ocular Surface Center, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
    • Allergan Inc, Irvine, California
    • Corresponding Author InformationInquiries to Stephen C. Pflugfelder, Ocular Surface Center, Cullen Eye Institute, Baylor College of Medicine, 6565 Fannin NC205, Houston, Texas 77030

,Accepted 21 August 2008.

References 

  1. Behrens A, Doyle JJ, MPH , Stern L, et al. Dysfunctional tear syndrome (A Delphi approach to treatment recommendations). Cornea. 2006;25:900–907
  2. Pflugfelder SC. Dry eye, focal points. San Francisco, California: American Academy of Ophthalmology; 2006;
  3. The Definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007;5:75–92
  4. Pflugfelder SC, de Paiva CS, Tong L, et al. Stress-activated protein kinase signaling pathways in dry eye and ocular surface disease. Ocul Surf. 2005;3:S154–S157
  5. Pflugfelder SC. Anti-inflammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337–342
  6. Alfonso A, Sobrin L, Monroy DC, et al. Tear fluid gelatinase B activity correlates with IL-1α concentration and fluorescein tear clearance. Invest Ophthalmol Vis Sci. 1999;40:2506–2512
  7. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Current Eye Research. 1999;19:201–211
  8. Jones DT, Yen M, Monroy D, et al. Evaluation of cytokine expression in the conjunctival epithelia of Sjögren's syndrome patients. Invest Ophthalmol Vis Sci. 1994;35:3493–3504
  9. Jones DT, Ji A, Monroy D, Pflugfelder SC. Evaluation of ocular surface cytokine, mucin, and cytokeratin expression in Sjögren syndrome. Adv Exp Med Biol. 1998;438:533–536
  10. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609–2614
  11. Rolando M, Barabino S, Mingari C, et al. Distribution of conjunctival HLA-DR expression and the pathogenesis of damage in early dry eyes. Cornea. 2005;24:951–954
  12. Baudouin C, Haouat N, Brignole F, et al. Immunopathological findings in conjunctival cells using immunofluorescence staining of impression cytology specimens. Br J Ophthalmol. 1992;76:545–549
  13. Gulati A, Sacchetti M, Bonini S, Dana R. Chemokine receptor CCR5 expression in conjunctival epithelium of patients with Dry Eye syndrome. Arch Ophthalmol. 2006;124:710–716
  14. Baudouin C, Liang H, Bremond-Gignac D, et al. CCR 4 and CCR 5 expression in conjunctival specimens as differential markers of T(H)1/T(H)2 in ocular surface disorders. J Allergy Clin Immunol. 2005;116:614–619
  15. Pflugfelder SC, Geerling G, Kinoshita S, et al. Management and Therapy of Dry Eye Disease: Report of the Management and Therapy Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf. 2007;5:163–178
  16. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107:631–639
  17. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444–457
  18. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with Dry Eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489–1496
  19. Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci. 2001;42:90–95
  20. De Paiva CS, Chen Z, Koch DD, et al. The incidence and risk factors for developing dry eye after myopic LASIK. Am J Ophthalmol. 2006;141:438–445
  21. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5:108–152
  22. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Assessment of the European classification criteria for Sjögren syndrome in a series of clinically defined cases: results of a prospective multicentre study (The European Study Group on Diagnostic Criteria for Sjögren Syndrome). Ann Rheum Dis. 1996;55:116–121
  23. Leonardi A, Curnow SJ, Zhan H, Calder VL. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy. 2006;36:777–784
  24. Sack R, Conradi L, Beaton A, et al. Antibody array characterization of inflammatory mediators in allergic and normal tears in the open and closed eye environments. Exp Eye Res. 2007;85:528–538
  25. Pflugfelder SC, de Paiva CS, Li D-Q, Stern ME. Epithelial-immune interaction in dry eye. Cornea. 2008;27:S9–S11
  26. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T-cell-mediated Sjögren's syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006;176:3950–3957
  27. De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Invest Ophthalmol Vis Sci. 2007;48:2553–2560
  28. Mika J, Korostynski M, Kaminska D, et al. Interleukin-1alpha has antiallodynic and antihyperalgesic activities in a rat neuropathic pain model. Pain. 2008;138:587–597
  29. Zanjani TM, Sabetkasaei M, Mosaffa N, et al. Suppression of interleukin-6 by minocycline in a rat model of neuropathic pain. Eur J Pharmacol. 2006;538:66–72

PII: S0002-9394(08)00690-9

doi: 10.1016/j.ajo.2008.08.032

American Journal of Ophthalmology
Volume 147, Issue 2 , Pages 198-205.e1 , February 2009

Article Tools

* Image Usage & Resolution